FinnCap restated their corporate rating on shares of OptiBiotix Health (LON:OPTI) in a research note released on Tuesday morning.
LON:OPTI opened at GBX 82 ($1.07) on Tuesday. OptiBiotix Health has a 12-month low of GBX 54.30 ($0.71) and a 12-month high of GBX 90 ($1.18).
In other OptiBiotix Health news, insider Neil Davidson purchased 103,000 shares of the company’s stock in a transaction that occurred on Monday, July 30th. The stock was purchased at an average price of GBX 99 ($1.29) per share, with a total value of £101,970 ($133,241.87). Also, insider Sean Christie purchased 125,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 10th. The stock was acquired at an average cost of GBX 80 ($1.05) per share, with a total value of £100,000 ($130,667.71).
OptiBiotix Health Company Profile
Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company is developing microbial strains, compounds, and formulations, which modulates the human microbiome and impacts lipid and cholesterol management, energy harvest, and appetite suppression activities.
Featured Story: Google Finance
Receive News & Ratings for OptiBiotix Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiBiotix Health and related companies with MarketBeat.com's FREE daily email newsletter.